DJIA 16,102.38 -272.38 -1.66%
NASDAQ 4,683.92 -49.58 -1.05%
S&P 500 1,921.22 -29.91 -1.53%
market minute promo

Novo Nordisk (NYSE: NVO)

54.31 -0.85 (-1.54%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

NVO $54.31 -1.54%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $54.49
Previous Close $55.16
Daily Range $53.90 - $54.55
52-Week Range $41.72 - $60.34
Market Cap $143.9B
P/E Ratio 0.00
Dividend (Yield) $0.73 (1.0%)
Ex-Dividend Date
Dividend Pay Date
Volume 667,145
Average Daily Volume 1,384,608
Current FY EPS $1.93




Drug Makers

Novo Nordisk (NVO) Description

Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals. Website:

News & Commentary

Is This Novo Nordisk's Next Blockbuster Drug?

Novo recently presented terrific data on its pipeline drug IDegLira, but U.S. approval is still far from certain. If it can gain approval, will it be meaningful to the company?

Bristol-Myers' (BMY) Opdivo Gets Priority Review, Shares Up

Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S.

Bristol-Myers/AbbVie Cancer Drug Gets Priority Review

Perrigo (PRGO) Buys Scar Management Brand from Enaltus

ESC- Case Builds For Jardiance

ITCA-650 Poised For Leadership In Type 2 Diabetes: Implications For Merck And Novo Nordisk

Bristol-Myers Inks Another Immuno-Oncology Drug Deal

Is Novo Nordisk (NVO) an Incredible Growth Stock? 3 Reasons Why It Will Be Tough to Beat

Novo's Oral GLP-1 Looks Sweeter

Benzinga's Top Initiations

See More NVO News...

NVO's Top Competitors

NVO $54.31 (-1.54%)
Current stock: NVO
PFE $31.37 (-1.63%)
Current stock: PFE
JNJ $91.31 (-1.44%)
Current stock: JNJ
RHHBY $33.36 (-0.12%)
Current stock: RHHBY